A Phase 1/2 interventional study of LOXO-292 in Non-Small Cell Lung Cancer, Medullary Thyroid Cancer and Colon Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 85 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 8th largest by enrollment of the 139 interventional ones that give a count, is one of 2 that started in 2017, is one of 13 in phase 1/2, reaches primary completion later than 6 of the 19 other live ones, and was the 121st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Austria and 26 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, France, Japan and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 41 · Phase 2 86 · Phase 3 25 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 857 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 109 across the 139 interventional studies, 1,076 across the 2 observational. Of the 121 that completed or were terminated, 81 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
5 of the studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06561685Eli Lilly and CompanyA Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
This is an open-label, multi-center Phase 1/2 study in participants with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: Phase 1 (dose escalation - completed) and phase 2 (dose expansion). Participants with advanced cancer are eligible if they have progressed on or are intolerant to available standard therapies, or no standard or available curative therapy exists, or in the opinion of the Investigator, they would be unlikely to tolerate or derive significant clinical benefit from appropriate standard of care therapy, or they declined standard therapy. A dose of 160 milligrams (mg) twice a day (BID) has been selected as the recommended phase 2 dose (RP2D). Approximately 875 participants with advanced solid tumors harboring a RET gene alteration in tumor and/or blood will be enrolled to one of six phase 2 cohorts:
Key Inclusion Criteria:
For Phase 1:
For Phase 2: As for phase 1 with the following modifications:
Cohorts 1 and 2:
Cohort 5:
Key Exclusion Criteria (Phase 1 and Phase 2):
active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or prolongation of the corrected (QTcF) greater than (>) 470 milliseconds (msec)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
Drug: LOXO-292
Oral LOXO-292
Also known as: Selpercatinib, LY3527723
Phase 1: Maximum Tolerated Dose (MTD)
The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.
Time frame: Cycle 1 (cycle length = 28 days)
Phase 1: Recommended Phase 2 Dose (RP2D)
Phase 1: RP2D
Time frame: Cycle 1 (cycle length = 28 days)
Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days. * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \[SAD\] for nodal lesions) of target lesions, taking as reference the baseline sum LD. ORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.
Time frame: Approximately for up to 7 years 8 months
Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])
Phase 1: Number of Participants with a TRAE(s) is reported.
Time frame: Up to 28 days
Phase 1: Number of Participants With an Abnormal Laboratory Values
Time frame: Up to 28 days
Phase 2: Overall Response Rate (ORR) Based on RECIST 1.1 or RANO, as Appropriate to Tumor Type
Phase 2: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type
Time frame: Approximately for up to 9 years 8 months
Phase 2: ORR (by Investigator)
Phase 2: ORR (by Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Best Change in Tumor Size From Baseline (by IRC and Investigator)
Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Duration of Response (DOR; by IRC and Investigator)
Phase 2: DOR (by IRC and Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Central Nervous System (CNS) ORR (by IRC)
Phase 2: CNS ORR (by IRC)
Time frame: Approximately for up to 9 years 8 months
Phase 2: CNS DOR (by IRC)
Phase 2: CNS DOR (by IRC)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Time to Any and Best Response (by IRC and Investigator)
Phase 2: Time to Any and Best Response (by IRC and Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: CBR (by IRC and Investigator)
Phase 2: CBR (by IRC and Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: PFS (by IRC and Investigator)
Phase 2: PFS (by IRC and Investigator)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Overall Survival (OS)
Phase 2: OS
Time frame: Approximately for up to 9 years 8 months
Phase 2: Percentage of Participants With Any Serious Adverse Event (SAE[s])
Phase 2: Percentage of Participants with any SAE(s)
Time frame: Approximately for up to 9 years 8 months
Phase 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib)
Phase 2: PK: AUC of LOXO-292 (Selpercatinib)
Time frame: Cycle 5 Day 1 (Cycle = 28 days)
Phase 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)
Phase 2: PK: Cmax of LOXO-292 (Selpercatinib)
Time frame: Cycle 5 Day 1 (Cycle = 28 days)
Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours
Time frame: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)
Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)
Time frame: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)
This study includes two parts: * Phase 1 (dose escalation) and; * Phase 2 (dose expansion) In Phase 1, participants received selpercatinib, with dosing based on body surface area. The Phase 2 portion of the study was opened after confirmation of the RP2D of 160 mg BID.
| Milestone | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Phase 2, Cohort 1: RET Fusion Solid Tumor | Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | Phase 2, Cohort 3: RET Mutant MTC | Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 10 | 16 | 12 | 1 | 20 | 19 | 764 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 6 | 10 | 16 | 12 | 1 | 20 | 19 | 764 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Phase 2, Cohort 1: RET Fusion Solid Tumor | Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | Phase 2, Cohort 3: RET Mutant MTC | Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 307 | 74 | 143 | 116 | 201 | 16 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 307 | 74 | 143 | 116 | 201 | 16 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 21 | 43 | 67 | 58 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 7 | 13 | 11 | 27 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 4 | 3 | 3 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 147 | 27 | 67 | 18 | 83 | 8 |
| Withdrew: Sponsor's decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 | 9 | 5 | 12 | 12 | 0 |
| Withdrew: Moved to commercial supply of drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 2 | 5 | 0 | 3 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Discontinued due to continued access | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 11 | 0 |
| Withdrew: Alternative treatment therapy/soc drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Enrolled for another trial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Participant's non-compliant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant unable to travel to site | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Study transfer to derive more clinical benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Developed a secondary malignancy and is no longer qualified for this study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.
| milligrams | Phase 1 - Selpercatinib (All Participants) |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) | 160 |
Phase 1: RP2D
| milligrams | Phase 1 - Selpercatinib (All Participants) |
|---|---|
| Phase 1: Recommended Phase 2 Dose (RP2D) | 160 |
Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days. * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \[SAD\] for nodal lesions) of target lesions, taking as reference the baseline sum LD. ORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.
| percentage of participants | Phase 2, Cohort 1: RET Fusion Solid Tumor | Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | Phase 2, Cohort 3: RET Mutant MTC | Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants |
|---|---|---|---|---|---|---|
| Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment | 62.9 (57.2 to 68.3) | 79.7 (68.8 to 88.2) | 77.6 (69.9 to 84.2) | 82.8 (74.6 to 89.1) | 57.2 (50.1 to 64.2) | 31.3 (11.0 to 58.7) |
Phase 1: Number of Participants with a TRAE(s) is reported.
| Participants | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s]) | 3 | 9 | 14 | 12 | 1 | 18 | 17 | 733 | 3 | 6 |
| Participants | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Number of Participants With an Abnormal Laboratory Values | 6 | 10 | 14 | 12 | 1 | 20 | 19 | 764 | 3 | 6 |
Phase 2: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type
Results for this outcome have not been posted.
Phase 2: ORR (by Investigator)
Results for this outcome have not been posted.
Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)
Results for this outcome have not been posted.
Phase 2: DOR (by IRC and Investigator)
Results for this outcome have not been posted.
Phase 2: CNS ORR (by IRC)
Results for this outcome have not been posted.
Phase 2: CNS DOR (by IRC)
Results for this outcome have not been posted.
Phase 2: Time to Any and Best Response (by IRC and Investigator)
Results for this outcome have not been posted.
Phase 2: CBR (by IRC and Investigator)
Results for this outcome have not been posted.
Phase 2: PFS (by IRC and Investigator)
Results for this outcome have not been posted.
Phase 2: OS
Results for this outcome have not been posted.
Phase 2: Percentage of Participants with any SAE(s)
Results for this outcome have not been posted.
Phase 2: PK: AUC of LOXO-292 (Selpercatinib)
Results for this outcome have not been posted.
Phase 2: PK: Cmax of LOXO-292 (Selpercatinib)
Results for this outcome have not been posted.
| nanogram*hour per milliliter (ng*h/mL) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours | 2240 ± 36 | 4570 ± 50 | 8450 ± 53 | 17100 ± 46 | — | 19400 ± 49 | 42200 ± 40 | 53700 ± 53 | NA ± NA | 87900 ± 20 |
| nanogram per milliliter (ng/mL) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) | 220 ± 14 | 275 ± 53 | 528 ± 55 | 1040 ± 46 | — | 1250 ± 45 | 2680 ± 27 | 3080 ± 48 | NA ± NA | 5130 ± 17 |
Collected over Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: 20 mg Selpercatinib QD | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Phase 1: 20 mg Selpercatinib BID | 0/10 (0%) | 8/10 (80%) | 10/10 (100%) |
| Phase 1: 40 mg Selpercatinib BID | 0/16 (0%) | 9/16 (56.3%) | 16/16 (100%) |
| Phase 1: 60 mg Selpercatinib BID | 0/12 (0%) | 7/12 (58.3%) | 12/12 (100%) |
| Phase 1: 160 mg Selpercatinib QD | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1: 80 mg Selpercatinib BID | 0/20 (0%) | 13/20 (65%) | 20/20 (100%) |
| Phase 1: 120 mg Selpercatinib BID | 0/19 (0%) | 11/19 (57.9%) | 19/19 (100%) |
| Phase 1: 160 mg Selpercatinib BID | 0/764 (0%) | 380/764 (49.7%) | 764/764 (100%) |
| Phase 1: 200 mg Selpercatinib BID | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1: 240 mg Selpercatinib BID | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2, Cohort 1: RET Fusion Solid Tumor | 147/307 (47.9%) | 187/307 (60.9%) | 307/307 (100%) |
| Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | 27/74 (36.5%) | 39/74 (52.7%) | 74/74 (100%) |
| Phase 2, Cohort 3: RET Mutant MTC | 67/143 (46.9%) | 93/143 (65%) | 143/143 (100%) |
| Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | 18/116 (15.5%) | 65/116 (56%) | 116/116 (100%) |
| Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | 83/201 (41.3%) | 114/201 (56.7%) | 201/201 (100%) |
| Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants | 8/16 (50%) | 8/16 (50%) | 16/16 (100%) |
| Event | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Phase 2, Cohort 1: RET Fusion Solid Tumor | Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | Phase 2, Cohort 3: RET Mutant MTC | Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blindness unilateralEye disorders | 0/6 | 0/10 | 0/16 | 0/12 | 1/1 | 0/20 | 0/19 | 0/764 | 0/3 | 0/6 | 0/307 | 0/74 | 1/143 | 0/116 | 0/201 | 0/16 |
| Blood bilirubin increasedInvestigations | 0/6 | 0/10 | 0/16 | 0/12 | 0/1 | 0/20 | 0/19 | 2/764 | 2/3 | 0/6 | 1/307 | 0/74 | 1/143 | 0/116 | 2/201 | 0/16 |
| EnterocolitisGastrointestinal disorders | 0/6 | 0/10 | 0/16 | 0/12 | 0/1 | 10/20 | 0/19 | 3/764 | 0/3 | 0/6 | 2/307 | 0/74 | 0/143 | 0/116 | 1/201 | 0/16 |
| Abdominal painGastrointestinal disorders | 2/6 | 1/10 | 1/16 | 0/12 | 0/1 | 2/20 | 1/19 | 21/764 | 0/3 | 0/6 | 7/307 | 1/74 | 4/143 | 4/116 | 12/201 | 0/16 |
| AscitesGastrointestinal disorders | 2/6 | 0/10 | 0/16 | 1/12 | 0/1 | 1/20 | 1/19 | 11/764 | 0/3 | 0/6 | 7/307 | 0/74 | 5/143 | 2/116 | 2/201 | 0/16 |
| CholecystitisHepatobiliary disorders | 1/6 | 0/10 | 0/16 | 0/12 | 0/1 | 0/20 | 0/19 | 6/764 | 1/3 | 0/6 | 2/307 | 0/74 | 1/143 | 2/116 | 3/201 | 0/16 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 0/10 | 1/16 | 0/12 | 0/1 | 0/20 | 0/19 | 9/764 | 1/3 | 0/6 | 5/307 | 1/74 | 0/143 | 1/116 | 4/201 | 0/16 |
| Aspartate aminotransferase increasedInvestigations | 0/6 | 0/10 | 1/16 | 0/12 | 0/1 | 0/20 | 0/19 | 9/764 | 1/3 | 0/6 | 5/307 | 1/74 | 0/143 | 1/116 | 4/201 | 0/16 |
| Blood alkaline phosphatase increasedInvestigations | 0/6 | 0/10 | 0/16 | 0/12 | 0/1 | 0/20 | 0/19 | 0/764 | 1/3 | 0/6 | 0/307 | 0/74 | 0/143 | 0/116 | 1/201 | 0/16 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 0/10 | 0/16 | 0/12 | 0/1 | 0/20 | 0/19 | 0/764 | 1/3 | 0/6 | 0/307 | 0/74 | 1/143 | 0/116 | 0/201 | 0/16 |
| Event | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Phase 2, Cohort 1: RET Fusion Solid Tumor | Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy | Phase 2, Cohort 3: RET Mutant MTC | Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy | Phase 2, Cohort 5: Advanced RET Altered Solid Tumor | Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blindness unilateralEye disorders | 0/6 | 0/10 | 0/16 | 0/12 | 1/1 | 0/20 | 0/19 | 0/764 | 0/3 | 0/6 | 0/307 | 0/74 | 1/143 | 0/116 | 0/201 | 0/16 |
| Periorbital oedemaEye disorders | 0/6 | 2/10 | 1/16 | 1/12 | 1/1 | 0/20 | 2/19 | 58/764 | 0/3 | 0/6 | 21/307 | 4/74 | 11/143 | 12/116 | 16/201 | 1/16 |
| Abdominal distensionGastrointestinal disorders | 3/6 | 0/10 | 1/16 | 2/12 | 1/1 | 5/20 | 5/19 | 110/764 | 0/3 | 2/6 | 36/307 | 6/74 | 28/143 | 28/116 | 30/201 | 1/16 |
| AscitesGastrointestinal disorders | 2/6 | 1/10 | 1/16 | 3/12 | 1/1 | 2/20 | 3/19 | 121/764 | 0/3 | 1/6 | 49/307 | 7/74 | 24/143 | 24/116 | 29/201 | 2/16 |
| DiarrhoeaGastrointestinal disorders | 3/6 | 5/10 | 7/16 | 5/12 | 1/1 | 9/20 | 12/19 | 394/764 | 1/3 | 3/6 | 169/307 | 32/74 | 67/143 | 61/116 | 102/201 | 9/16 |
| VomitingGastrointestinal disorders | 2/6 | 6/10 | 5/16 | 2/12 | 1/1 | 6/20 | 4/19 | 214/764 | 2/3 | 2/6 | 82/307 | 21/74 | 47/143 | 34/116 | 57/201 | 3/16 |
| Face oedemaGeneral disorders | 0/6 | 1/10 | 1/16 | 1/12 | 1/1 | 0/20 | 2/19 | 86/764 | 1/3 | 0/6 | 45/307 | 6/74 | 14/143 | 8/116 | 20/201 | 0/16 |
| FatigueGeneral disorders | 3/6 | 6/10 | 11/16 | 4/12 | 1/1 | 7/20 | 10/19 | 298/764 | 3/3 | 3/6 | 111/307 | 31/74 | 56/143 | 64/116 | 80/201 | 4/16 |
| Oedema peripheralGeneral disorders | 4/6 | 6/10 | 4/16 | 3/12 | 1/1 | 9/20 | 8/19 | 284/764 | 1/3 | 2/6 | 121/307 | 20/74 | 64/143 | 42/116 | 69/201 | 6/16 |
| Blood creatinine increasedInvestigations | 0/6 | 1/10 | 3/16 | 2/12 | 1/1 | 5/20 | 3/19 | 225/764 | 0/3 | 1/6 | 78/307 | 15/74 | 40/143 | 54/116 | 50/201 | 4/16 |
All enrolled Participants.
| Age, Categorical(Participants) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 3 |
| Between 18 and 65 years | 5 | 6 | 11 | 9 | 0 | 11 | 13 | 495 | 2 | 4 | 556 |
| >=65 years | 1 | 4 | 5 | 3 | 1 | 8 | 6 | 267 | 1 | 2 | 298 |
| Sex: Female, Male(Participants) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 5 | 7 | 5 | 0 | 7 | 10 | 378 | 1 | 4 | 421 |
| Male | 2 | 5 | 9 | 7 | 1 | 13 | 9 | 386 | 2 | 2 | 436 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 38 | 0 | 0 | 40 |
| Not Hispanic or Latino | 6 | 9 | 15 | 12 | 1 | 20 | 18 | 700 | 3 | 6 | 790 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 27 |
| Race (NIH/OMB)(Participants) | Phase 1: 20 mg Selpercatinib QD | Phase 1: 20 mg Selpercatinib BID | Phase 1: 40 mg Selpercatinib BID | Phase 1: 60 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib QD | Phase 1: 80 mg Selpercatinib BID | Phase 1: 120 mg Selpercatinib BID | Phase 1: 160 mg Selpercatinib BID | Phase 1: 200 mg Selpercatinib BID | Phase 1: 240 mg Selpercatinib BID | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Asian | 1 | 0 | 1 | 1 | 0 | 2 | 3 | 198 | 0 | 1 | 207 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 24 | 0 | 0 | 27 |
| White | 5 | 10 | 13 | 10 | 1 | 16 | 15 | 502 | 3 | 5 | 580 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 36 | 0 | 0 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Feb 2025, 93 months.
Results were first posted in Apr 2026, 1 year 2 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 93 months is above that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib
Carcinoma, Non-Small-Cell Lung →